阿托伐他汀钙治疗老年心力衰竭合并阵发性房颤的临床观察

目的：观察阿托伐他汀钙治疗老年心力衰竭合并阵发性房颤的临床疗效及安全性。方法：将149例老年心力衰竭合并阵发性房颤患者随机分为对照组（73例）和治疗组（76例）。对照组患者给予常规治疗；治疗组患者在对照组治疗的基础上给予阿托伐他汀钙20mg，1次／晚。两组患者疗程均为1年。评价两组患者的临床疗效；观察两组患者治疗前后甘油三酯（TG）、胆固醇（TC）、心输出量（CO）、左心室射血分数（LVEF）及左心房内径的变化；观察两组患者房颤和缺血性事件的发生率及不良反应发生情况。结果：治疗组患者总有效率显著高于对照组，两组比较差异有统计学意义（P〈0．05）。治疗后，治疗组患者TG、TC和左心房内径均显著低于对照组，CO、LVEF显著高于对照组，两组比较差异均有统计学意义（P〈0．05）。治疗组患者阵发性房颤复发率、转为持续性或永久性房颤发生率、缺血性事件发生率均显著低于对照组，两组比较差异有统计学意义（P〈0．05）。治疗期间两组患者均未见明显不良反应发生。结论：阿托伐他汀钙治疗老年心力衰竭合并阵发性房颤具有较好的疗效，且安全性较好。

Clinical Observation of Atorvastatin Calcium in the Treatment of Senile Heart Failure Combined with Paroxysmal Atrial Fibrillation

OBJECTIVE： To observe clinical efficacy and safety of atorvastatin calcium in the treatment of senile heart failure complicating with paroxysmal atrial fibrillation. METHODS： 149 cases of senile heart failure complicating with paroxysmal atrial fibrillation were randomized into control group （73 cases） and treatment group （76 cases）. Control group was given conventional treatment. Treatment group was given atorvastatin calcium 20 mg once a night on the basis of control group. All patients were treat- ment for one year. Clinical efficacies of 2 groups were evaluated. The changes of TG, TC, CO, LVEF, left atrial diameter were ob- served in 2 groups before and after treatment. The incidence of persistent or permanent atrial fibrillation, the incidence of ischemic events and ADR were observed in 2 groups. RESULTS： Total effective rate of treatment group was significantly higher than that of control group; there was statistical significance （P〈0.05）. TG, TC and left atrial cliameter of treatment group were significantly lower than those of control group, CO and LVEF of treatment group were higher than control group; there was statistical signifi- cance （P〈0.05）. The recurrence rate of paroxysmal atrial fibrillation, the incidence of persistent or permanent atrial fibrillation and incidence of ischemic events in treatment group were significantly lower than in control group; there was statistical significance （P〈0.05）. Adverse drug reactions were not found. CONCLUSIONS： Atorvastatin calcium is effective and safety in the treatment of senile heart failure complicating with paroxysmal atrial fibrillation.